

Revision date: 04-Jan-2007

Version: 1.1

Page 1 of 7

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc **Pfizer Pharmaceuticals Group** 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number:

Pfizer Ltd **Ramsgate Road** Sandwich, Kent **CT13 9NJ United Kingdom** +00 44 (0)1304 616161

CHEMTREC (24 hours): 1-800-424-9300

Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Pantoprazole Tablets

SOMAC Trade Name: **Chemical Family:** Mixture Intended Use: Pharmaceutical product for the treatment of gastrointestinal disorders

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Titanium dioxide	13463-67-7	236-675-5	*
Propylene glycol	57-55-6	200-338-0	*
Sodium lauryl sulfate	151-21-3	205-788-1	*
Calcium stearate	1592-23-0	216-472-8	*
Sodium carbonate	497-19-8	207-838-8	*
Pantoprazole Sodium Sesquihydrate	164579-32-2	Not listed	20 or 40 mg***

Ingredient	CAS Number	EU EINECS List	%
Mannitol	69-65-8	200-711-8	*
Polysorbate 80	9005-65-6	Not listed	*
Hypromellose	9004-65-3	Not listed	*
Triethyl Citrate	77-93-0	201-070-7	*
Crospovidone	9003-39-8	Not listed	*
Povidone	9003-39-8	Not listed	*
Ferric oxide yellow	51274-00-1	257-098-5	*

Additional Information:

* Proprietary

*** per tablet/capsule/lozenge/suppository

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: Signal Word:

Tablet WARNING

Statement of Hazard:

May be harmful if swallowed. Possible carcinogen

Additional Hazard Information:

Short Term:	May be harmful if swallowed. (based on animal data) Accidental ingestion may cause effects similar to those seen in clinical use.
Known Clinical Effects:	Adverse effects most commonly reported in clinical use include headache, diarrhea, nausea, and flatulence. May cause mild skin rash.
EU Indication of danger:	Harmful Carcinogenic: Category 2
EU Hazard Symbols:	
EU Risk Phrases:	R22 - Harmful if swallowed. R45 - May cause cancer.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASU	IRES
Eye Contact:	Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.
Skin Contact:	Remove contaminated clothing and wash exposed area with soap and water. Obtain medical assistance if irritation occurs. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
5. FIRE FIGHTING MI	EASURES

Extinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Products:	Carbon monoxide, carbon dioxide, oxides of nitrogen, and fluorine-containing compounds
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self- contained breathing apparatus.
Fire / Explosion Hazards:	Not determined

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.	
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.	

Material Name: Pantoprazole Tablet Revision date: 04-Jan-2007		Page 3 of 7 Version: 1.1
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for avoid environmental release.	disposal. Care should be taken to
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected a situations immediately. Clean up operations should only be u	
7. HANDLING AND STORAGE		
General Handling:	If tablets or capsules are crushed and/or broken, avoid breath eyes.	ning dust and avoid contact with
Storage Conditions:	Store as directed by product packaging.	
8. EXPOSURE CONTROLS / P	ERSONAL PROTECTION	
Titanium dioxide OSHA - Final PELS - TWAs: ACGIH Threshold Limit Value Australia TWA	TWA) = 15 mg/m ³ TWA total = 10 mg/m ³ TWA = 10 mg/m ³ TWA	
Propylene glycol Australia TWA	= 10 mg/m³ TWA = 150 ppm TWA = 474 mg/m³ TWA	
Sodium lauryl sulfate Pfizer OEL TWA-8 Hr: Pfizer STEL	0.3 mg/m³ 0.75 mg/m³	
Calcium stearate ACGIH Threshold Limit Value Australia TWA The exposure limit(s) listed for s	TWA) = 10 mg/m ³ TWA except stearai = 10 mg/m ³ TWA lid components are only relevant if dust may be generated.	tes of toxic metals
Engineering Controls:	Engineering controls should be used as the primary means to	o control exposures.
Personal Protective Equipment:		
Hands:	Not required for the normal use of this product. Wear protect	ive gloves when working with
Eyes:	large quantities. Not required under normal conditions of use. Wear safety gla	asses or goggles if eye contact is
Skin:	possible. Not required for the normal use of this product. Wear protection	ive clothing when working with
Respiratory protection:	large quantities. Not required for the normal use of this product. If the applical (OEL) is exceeded, wear an appropriate respirator with a prot exposures to below the OEL.	

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:	Tablet	Color:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

10. STABILITY AND REACTIVITY

Stability: Conditions to Avoid: Incompatible Materials: Stable under normal conditions of use. Not determined As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information:

The information included in this section describes the potential hazards of various forms of the active ingredients. The remaining information describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Pantoprazole Sodium

RatOralLD 50747 mg/kgMouseOralLD 50> 1000 mg/kgRatIntravenousLD 50256 mg/kg

Mannitol

Rat Oral LD 50 13500 mg/kg Mouse Oral LD 50 22 g/kg

Povidone

Rat Oral LD50 100 g/kg

Polysorbate 80

Rat Oral LD50 25 g/kg

Hypromellose Rat Oral LD50 > 10,000 mg/kg

Titanium dioxide

Rat Oral LD50 > 7500 mg/kg Rat Subcutaneous LD 50 50 mg/kg

Propylene glycol

Mouse Oral LD50 22,000 mg/kg Rat Oral LD50 20,000 mg/kg Rabbit Dermal LD50 20,800 mg/kg

Sodium lauryl sulfate Rat Oral LD50 1288 mg/kg Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Propylene glycol

Skin Irritation Rabbit Mild Eye Irritation Rabbit Mild

Sodium lauryl sulfate

Eye Irritation Rabbit Severe Skin Irritation Rabbit Severe

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Pantoprazole

Reproductive & Fertility-Males Oral 500 mg/kg/day NOEL No effects at maximum dose Rat Rat Reproductive & Fertility - Females No effects at maximum dose Oral 450 mg/kg/day NOEL Fertility and Embryonic Development Rat Oral 450 mg/kg/day NOEL Not Teratogenic Fertility and Embryonic Development Rabbit Oral 40 mg/kg/day NOEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Pantoprazole

Chromosome AberrationHuman LymphocytesPositiveMicronucleusMousePositiveMammalian Cell MutagenicityChinese Hamster Ovary (CHO) cellsPositiveIn Vivo DNA Binding AssayRatEquivocalIn Vivo Chromosome AberrationRat Bone MarrowNegative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Pantoprazole

24 Month(s)	Rat	Oral	0.5 mg/kg/day LOEL Tumors, Gastrointestinal system, Live	er
24 Month(s)	Rat	Oral	5 mg/kg/day LOEL Tumors, Gastrointestinal system	
24 Month(s)	Mous	e Oral	150 mg/kg/day LOEL Tumors, Liver	
24 Month(s)	Rat	Oral	200 mg/kg/day LOEL Tumors, Thyroid	

Carcinogen Status:	See below	
Povidone	0	
IARC:	Group 3	
Crospovidone		
IARC:	Group 3	
Titanium dioxide		
IARC:	Group 2B	
OSHA:	Present	

12. ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: EU Indication of danger:	T Harmful Carcinogenic: Category 2
EU Risk Phrases:	R22 - Harmful if swallowed. R45 - May cause cancer.
EU Safety Phrases:	S22 - Do not breathe dust. S53 - Avoid exposure - obtain special instructions before use. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.

OSHA Label: WARNING May be harmful if swallowed. Possible carcinogen

Canada - WHMIS: Classifications

WHMIS hazard class: Class D, Division 2, Subdivision A



Mannitol Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	Present Present 200-711-8
Polysorbate 80 Inventory - United States TSCA - Sect. 8(b) Australia (AICS):	XU Present
Titanium dioxide Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	Present Present 236-675-5
Propylene glycol Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	Present Present 200-338-0

Material Name: Pantoprazole Tablets Revision date: 04-Jan-2007

Page 7 of 7 Version: 1.1

Hypromellose Inventory - United States TSCA - Sect. 8(b) Australia (AICS): Standard for the Uniform Scheduling for Drugs and Poisons:	XU Present Schedule 4
Triethyl Citrate Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	Present Present 201-070-7
Sodium lauryl sulfate Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	Present Present 205-788-1
Calcium stearate Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	Present Present 216-472-8
Crospovidone Inventory - United States TSCA - Sect. 8(b) Australia (AICS):	XU Present
Povidone Inventory - United States TSCA - Sect. 8(b) Australia (AICS):	XU Present
Sodium carbonate Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	Present Present 207-838-8
Ferric oxide yellow Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	Present Present 257-098-5

16. OTHER INFORMATION

Reasons for Revision:

Updated Section 3 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information.

Prepared by:

Toxicology and Hazard Communication Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet